Life-Science Tools & Biotech Quality Compounders

While the market de-risks crowded AI hardware, Fisher-style quality growth lives in life-science tools and biotech: decades-long R&D pipelines, razor-and-blade consumables economics, and durable 20%+ margins that compound regardless of the AI capex cycle. Policy momentum behind transatlantic biotech and biomanufacturing capacity adds a multi-year tailwind to non-China research infrastructure. These are companies with deep management benches, pricing power, and reinvestment runways measured in decades, not quarters. Catalysts: - 2026-10-08 CEPA urges transatlantic biotech partnership versus China (https://cepa.org/comprehensive-reports/forging-a-transatlantic-biotechnology-partnership-to-confront-the-china-conflict/) Launch basket (equal weight): TMO, DHR, IDXX, ZTS, VRTX, REGN, AMGN, ABBV, MRNA, MRK Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.